AEON Biopharma (AEON) Common Equity (2020 - 2026)
AEON Biopharma (AEON) posted Common Equity of -$55.0 million for Q4 2025, down 176.91% sequentially from -$19.9 million in Q3 2025, and down 92.61% YoY from -$744.7 million in Q4 2024.
AEON Biopharma (AEON) Common Equity (2020 - 2026) Analysis & Trends
AEON Biopharma has reported Common Equity for 6 years, with the latest figure at -$55.0 million in Q4 2025.
- Quarterly Common Equity fell 92.61% year-over-year to -$55.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$55.0 million (down 92.61% YoY) and the FY2025 annual result came in at -$55.0 million, down 92.61% from the prior year.
- Common Equity slipped to -$55.0 million in Q4 2025 per AEON's latest filing, from -$19.9 million in the prior quarter.
- Over five years, Common Equity peaked at -$11.3 million in Q1 2025 and troughed at -$286.7 million in Q1 2023.
- A 5-year average of -$113.7 million and a median of -$43.6 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2021 and 2025: Common Equity slumped 1045420.38% in 2021, then soared 94.29% in 2025.
- Over 5 years, Common Equity stood at -$223.8 million in 2021, then declined by 20.82% to -$270.4 million in 2022, then surged by 43.4% to -$153.0 million in 2023, then surged by 81.33% to -$28.6 million in 2024, then sank by 92.61% to -$55.0 million in 2025.
- According to Business Quant data, Common Equity over the past three periods registered -$55.0 million, -$19.9 million, and -$15.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | AEON Biopharma | 9.71 Mn | 6.28 Mn | - | -15.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.36 Mn |
| Dec 31, 2025 | -55.03 Mn |
| Sep 30, 2025 | -19.87 Mn |
| Jun 30, 2025 | -15.85 Mn |
| Mar 31, 2025 | -11.32 Mn |
| Dec 31, 2024 | -28.57 Mn |
| Sep 30, 2024 | -32.09 Mn |
| Jun 30, 2024 | -27.95 Mn |
| Mar 31, 2024 | -198.38 Mn |
| Dec 31, 2023 | -153.04 Mn |
| Sep 30, 2023 | -128.40 Mn |
| Jun 30, 2023 | -283.89 Mn |
| Mar 31, 2023 | -286.69 Mn |
| Dec 31, 2022 | -270.41 Mn |
| Sep 30, 2022 | -237.59 Mn |
| Jun 30, 2022 | -228.23 Mn |
| Mar 31, 2022 | -14.16 Mn |
| Dec 31, 2021 | -223.82 Mn |
| Sep 30, 2021 | -17.18 Mn |
| Jun 30, 2021 | -22.84 Mn |